# Bristol-Myers Squibb Stock: Growth Opportunity

> Bristol-Myers Squibb's strong Q2 earnings and dividend offer a pullback opportunity.
- Title: Bristol-Myers Squibb Stock: Growth Opportunity · Seekingalpha
- Summary: Bristol-Myers Squibb's strong Q2 earnings and dividend offer a pullback opportunity. Bristol-Myers Squibb's Q2 earnings triple-play with strong growth and…
- Keywords: bristol-myers-squibb, bmy, nyse, dividend, q2 earnings, patent cliffs, free cash flow, money, business, Bristol-Myers, Squibb, Stock
- Source: Seekingalpha — https://seekingalpha.com/article/4952628-bristol-myers-squibb-balanced-segment-growth-the-pullback-is-an-opportunity
- Author: Mike Zaccardi, CFA, CMT
- Published: 2026-10-07T23:17:20+00:00
- Read time: 1 min
- Topics: bristol-myers-squibb, bmy, nyse, dividend, q2 earnings, patent cliffs, free cash flow, money, business
## Q2 Earnings Triple-Play
Bristol-Myers Squibb delivered strong Q2 earnings with raised FY 2026 sales guidance and robust growth in both legacy and new products.
## Dividend Yield and Valuation
Bristol-Myers Squibb is reiterated as a buy with an attractive 4.23% dividend yield and strong valuation metrics.
## Patent Cliffs and EPS Decline
Despite looming patent cliffs and projected EPS declines post-2026, Bristol-Myers Squibb benefits from high free cash flow and recent bullish EPS revisions.
## Technical Support and Resistance
Technical support at the 200-day moving average and strong free cash flow suggest resilience, though resistance at $63 and pipeline execution remain key watchpoints.
## Pullback Opportunity
Bristol-Myers Squibb's stock pullback presents an opportunity for investors given strong fundamentals and recent earnings performance.
## Key takeaway

Bristol-Myers Squibb's Q2 earnings triple-play with strong growth and dividend yield presents a buying opportunity despite patent cliffs.